Time to progression to castration-resistant prostate cancer after commencing combined androgen blockade for advanced hormone-sensitive prostate cancer-Reference-Cited by-同舟云学术

Time to progression to castration-resistant prostate cancer after commencing combined androgen blockade for advanced hormone-sensitive prostate cancer

Published:2018-12-11 Issue:97 Volume:9 Page:36966-36974
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Tamada Satoshi¹,Iguchi Taro¹,Kato Minoru¹,Asakawa Jumpei¹,Kita Kazuaki¹,Yasuda Sayaka¹,Yamasaki Takeshi¹,Matsuoka Yudai²,Yamaguchi Kazuyuki²,Matsumura Kentaro²,Go Ishun²,Ohmachi Tetsuji²,Nakatani Tatsuya¹

Affiliation:

1. Department of Urology, Osaka City University Graduate School of Medicine, Abeno-ku, Osaka 545-8585, Japan

2. Department of Urology, Bell Land General Hospital, Naka-ku, Sakai City, Osaka 599-8247, Japan

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Homologous Recombination Repair Gene Mutations in Prostate Cancer: Prevalence and Clinical Value;Advances in Therapy;2024-05-20

2. Relugolix vs. Leuprolide Effects on Castration Resistance-Free Survival from the Phase 3 HERO Study in Men with Advanced Prostate Cancer;Cancers;2023-10-05

3. Early Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer;Journal of Clinical Oncology;2023-07-10

4. Metastatic prostate cancer diagnosed by fine‐needle aspiration: Contemporary cytopathologic and biomarker assessment with clinical correlates;Cancer Cytopathology;2022-10-20

5. Flare on [18F]PSMA-1007 PET/CT after short-term androgen deprivation therapy and its correlation to FDG uptake: possible marker of tumor aggressiveness in treatment-naïve metastatic prostate cancer patients;European Journal of Nuclear Medicine and Molecular Imaging;2022-09-26